Analyst: Intuitive Surgical Is Moving Into Its 'Most Catalyst Rich' Cycle Ever
Intuitive Surgical, Inc. (NASDAQ: ISRG) reported Tuesday its first quarter results, which came in ahead of expectations and sent the stock surging to new all-time highs. Yet the company still faces its "most catalyst rich" cycle ever, according to Morgan Stanley.
The Analyst
Morgan Stanley's David Lewis maintains an Overweight rating on Intuitive Surgical with a price target lifted from $500 to $525.
The Thesis
Intuitive Surgical's results came in "materially stronger" than Lewis' already bullish expectations, the analyst said in a note. The strength seen in the quarter came in a big part from procedure growth of 15 percent from a year ago and encouraging gross system placements, which was the second strongest ever.
Lewis said investors should have confidence that Intuitive Surgical will proceed in multiple catalysts that have yet to play out. These include:
SP approval and additional filings after a "normal" process in which the FDA asked questions;
Renewal of China quota where demand for robotic surgery is "meaningful"; and
Ongoing progress in Japan where the total addressable market is more than 200,000 procedures versus 30,000 prior from prostatectomy and partial nephrectomy.
Price Action
Shares of Intuitive Surgical hit a new all-time high of $471.40 Wednesday, higher by more than 8 percent on the day.
The Companies That Led 2017's Biotech Rally
What's Powering This Robotics ETF
Image Credit: ©[2016] Intuitive Surgical, Inc. (©[2016] Intuitive Surgical, Inc.), via Wikimedia Commons
Latest Ratings for ISRG
Date | Firm | Action | From | To |
---|---|---|---|---|
Apr 2021 | Citigroup | Initiates Coverage On | Buy | |
Mar 2021 | Piper Sandler | Maintains | Neutral | |
Jan 2021 | Raymond James | Maintains | Outperform |
View More Analyst Ratings for ISRG
View the Latest Analyst Ratings
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: China David LewisAnalyst Color Earnings News Price Target Top Stories Analyst Ratings Best of Benzinga